Introduction
Patients with type 2 diabetes mellitus are at high risk of developing macrovascular complications, such as CHD, the leading cause of death in this population. 1 Epidemiological evidence suggests that hyperinsulinaemia and insulin resistance are independent risk factors for CHD and atherosclerosis in patients with type 2 diabetes and the metabolic syndrome. 2, 3 Therefore, prevention and treatment strategies should not only target hyperglycaemia, but also insulin resistance and its associated complications (dyslipidaemia, endothelial dysfunction, increased blood pressure, increased thrombosis and decreased fibrinolysis). This should result in a better management of the global cardiovascular risk of type 2 diabetes patients.
The recent development of PPAR agonists seems to offer new perspectives for the pharmacological management of type 2 diabetes, the metabolic syndrome and likely also its cardiovascular complications. PPARs are ligand-activated transcription factors belonging to the nuclear receptor superfamily. PPAR ligands can positively or negatively regulate gene expression. 4 PPARs can also repress gene expression independently of DNA binding by altering other signalling pathways, including those involved in the inflammatory response. 5 The PPAR family consists of three members, α, γ, and β/δ. 4 While FA and FA-derived compounds were identified as potential natural ligands for PPARα and PPARγ, fibrates and TZDs are synthetic PPARα and PPARγ agonists, respectively. The present review will focus on the effects of PPARα and PPARγ agonists on vascular function and atherogenesis, and will highlight their potential beneficial cardioprotective effects in patients with type 2 diabetes and the metabolic syndrome. Although some studies refer to troglitazone, a TZD withdrawn because of liver toxicity, we have preferentially described results of studies using the current TZDs rosiglitazone and pioglitazone.
Pleiotropic actions of PPARs in the vasculature
Based on the findings that both PPARα and PPARγ are expressed in ECs, 6 VSMCs, 7 human monocytes/macrophages. 8 T lymphocytes, 9 as well as in atherosclerotic lesions in vivo 10 it has been hypothesised that PPARs could exert modulatory actions on these vascular cells and influence atherogenesis. Early lipid accumulation in the arterial wall during atherogenesis 11 can be modified by PPAR activation in several ways (figure 1). Most of the initial studies were in vitro experiments, but now in vivo reports are appearing in mice, and also humans (for more detailed review, see reference 12).
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Endothelial function
PPARα and PPARγ activators regulate chemoattraction and cellular adhesion to endothelial cells by reducing cytokine-induced expression of VCAM-1 and ICAM-1, which play a critical role in the recruitment of lymphocytes and monocytes to atherosclerotic lesions. 6 In vitro experiments on human ECs indicated that activation of PPARγ inhibits the expression of the monocyte-specific chemokine MCP-1. 13 Furthermore, both PPARα and γ agonists modulate T-lymphocyte proliferation and immune activation. 14, 15 Of pathophysiological relevance, TZDs significantly reduce monocyte/macrophage recruitment to atherosclerotic lesions, in an in vivo mouse model of atherosclerosis (i.e. apoE-null mice). PPAR agonists also regulate vascular tone by modulating the release of NO, a mediator of vasodilation and ET-1, a vasoconstrictor peptide and inducer of VSMC proliferation. Both PPARα and PPARγ activation have been shown to enhance eNOS expression and NO release. 17, 18 Conversely, PPARα and PPARγ activators diminish the expression of ET-1. 19 Thus, PPARs may counterbalance endothelial dysfunction by acting on different biochemical parameters. It should be noted that PPARγ may play a role in growth factor-induced angiogenesis. PPARγ activation inhibits vascular endothelial growth factor receptor expression and limits angiogenesis in vitro and in vivo in rats. 20 The inhibition of neoangiogenesis may be beneficial due to a decreased plaque formation and intraplaque haemorrhage, but it cannot be excluded that such activity could also reduce the development of protective collaterals in patients with CHD. Additional studies are needed to answer this question.
Lipid accumulation within the plaque
PPARα and PPARγ are present in monocytes, and their expression is up-regulated during differentiation into macrophages. Although PPARs do not influence macrophage differentiation, they play an important role in regulating cholesterol homeostasis. 11 The RCT pathway mediates the transport of cholesterol from peripheral cells back to the liver, where it is eliminated into the bile. Cholesterol efflux, the first step of the RCT pathway, occurs either via passive diffusion or via transmembrane transporters, such as the SRB1/CLA1 and the ABCA1 proteins. In human macrophages, both PPARα and PPARγ activators induce protein levels of SRB1/CLA1 and ABCA1, thereby leading to a higher cholesterol efflux from macrophages. 10, 21 24 In addition, the conditional disruption of PPARγ in macrophages resulted in a reduced cholesterol removal from macrophages. 25 Thus, in this model, the lowered expression of ABCA1 and ABCG1 physiologically counterbalances the decrease of CD36 expression. Taken together, these data suggest an overall beneficial effect of PPARα and PPARγ activators on fatty streak formation in rodents in vivo, and in vitro in human macrophages.
Local inflammatory response and plaque stability
The activation of cells in atherosclerotic lesions leads to the release of proinflammatory molecules and the onset of a chronic inflammatory response. Various studies have demonstrated that PPARα and PPARγ activators inhibit the expression of inflammatory response genes, such as cytokines (TNFα, interferon γ, interleukins), metalloproteases, and acute-phase reactants (CRP, fibrinogen). PPARα and PPARγ agonists exert anti-inflammatory activities in various immunological and vascular cell types, such as monocytes/macrophages, ECs, VSMCs, and T lymphocytes. 5, 12 Incubation of human monocytes with PPARγ ligands inhibits the production of inflammatory cytokines such as TNFα, IL-1β‚ and IL-6. 26 PPARα activators modify inflammatory SMC activation by inhibiting IL-1 induced production of IL-6 and prostaglandins and by reducing the expression of cyclooxygenase-2.
7 T lymphocytes, differentiated in the subendothelium to Th1-cells in response to oxidised-LDL, may also contribute to the vascular inflammatory response during atherogenesis.
Plaque rupture is the end stage of the atherogenic process, leading to thrombus formation, occlusion, with an acute coronary syndrome as a clinical consequence. PPARα and PPARγ agonists reduce the expression of matrix metalloproteinase-9, a secreted matrix-degrading protein, by monocytes/ macrophages. 27 Such activity is thought to promote the stability of advanced lesions. PPARα and PPARγ agonists can also modulate platelet aggregation by reducing the expression of both tissue factor and platelet activating factor receptor in human monocytes/macrophages 28, 29 and decreasing the production of thromboxane A 2 , a potent platelet aggregation inducer. 30 TZDs and fibrates also modulate the secretion of the thrombosisinducer PAI-1. 31, 32 The cumulative effect of these actions should decrease the thrombogenic response.
Vascular smooth muscle cell proliferation
Recent studies highlighted the role of PPARγ in DNA replication and cell-cycle progression in VSMCs. TZDs inhibit VSMC growth and proliferation through increased levels of the cyclindependent kinase inhibitor p27 and decreased phosphorylation of the retinoblastoma protein, thus leading to cell-cycle arrest. 33 Of physiological relevance, TZD treatment causes a significant reduction of intimal hyperplasia in vivo in a rat model of vascular injury. 34 It should be noted that a similar antiproliferative action was also described for PPARα agonists, by a mechanism involving an increased expression of the cyclin-dependent kinase inhibitor p16.
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Vascular insulin resistance
Under physiological conditions, insulin has anti-inflammatory and vasodilatory functions in the vasculature. 3 Several independent studies in humans have demonstrated the importance of insulin sensitivity in the regulation of endothelial function. 36 The molecular mechanisms of how insulin resistance and endothelial dysfunction might be connected are still unclear. The cellular response to insulin is mediated by means of two classical pathways involving PI3K and MAPK. Interestingly, insulin regulation of eNOS and insulin-induced anti-inflammatory effects are mediated through the PI3K pathway. Indeed, pharmacological inhibition of the PI3K pathway in ECs leads to a blockade of insulinstimulated NO signalling and vasodilation. Under this condition, insulin (1-10 nmol/l)-induced signalling through the MAPK pathway is still operative and enhances the expression of ET-1, adhesion molecules and monocyte/macrophage recruitment. 37 Taken together, these findings suggest that a differential sensitivity of the MAP kinase versus PI3K signalling pathways to insulin in ECs may contribute to the vascular dysfunction in insulin-resistant subjects (figure 2).
The suppression of eNOS results in hypertension, peripheral insulin resistance, and hyperlipidaemia in mice. 38 Defective NO synthesis may therefore link metabolic and cardiovascular disease in diabetes, and TZD-induced eNOS expression may contribute to their cardioprotective and insulin-sensitising effects. However, EC insulin receptor deficiency did not alter vascular development or glucose homeostasis, 39 despite a 30-60% reduction of eNOS and ET-1 mRNA expression. Studies are needed to investigate the role and consequences of PPAR activation on vascular insulin resistance and to unravel whether these agonists act via a direct action on the vasculature or rather indirectly via improvement of whole body insulin sensitivity.
Clinical evidence for cardioprotective effects of PPARα and γ agonists PPARγ agonists
Large prospective studies have clearly shown that intensive glycaemic control significantly improves microvascular complications in type 1 and type 2 diabetes. 40, 41 However, glucose-lowering intervention studies have not always demonstrated a marked reduction in the incidence of cardiovascular events. Since TZDs exert numerous beneficial vascular effects, at least in vitro, these agents appear good candidates to reduce CVD in subjects with type 2 diabetes mellitus. To verify this hypothesis several large prospective clinical trials are currently underway to determine whether treatment with pioglitazone (PROactive) 42 or rosiglitazone (RECORD) will influence the macrovascular events in patients with type 2 diabetes mellitus (table 1) .
At present, the results of several smaller studies on intermediate endpoints argue in favour of a beneficial vascular effect of TZDs. Direct assessment of endothelial function in response to TZD treatment has been evaluated by measurements of FMD or PWV, which are known to be prognostic predictors of CHD risk. 43 In several studies, TZDs significantly improved endotheliumdependent FMD in patients with type 2 diabetes mellitus 44, 45 or metabolic syndrome. 46 Most of these studies did not observe any improvement in endothelium-independent nitroglycerin-induced vasodilation, suggesting that TZDs act mainly at the level of ECs rather than on SMCs. As suggested by initial studies with troglitazone, the beneficial effect of TZDs on endothelial function may be indirect through an improvement of insulin resistance. 47 However, a recent study did not observe any correlation between the vascular protective effect of pioglitazone and insulin sensitivity in patients with type 2 diabetes mellitus, reinforcing the hypothesis of a direct action of TZDs on the vasculature. 44 Of more direct clinical relevance, treatment with different TZDs decreased the carotid arterial intima-media wall thickness in type 2 diabetes mellitus patients. 48 Furthermore, results from an intravascular ultrasound scanning study demonstrated that pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in a small group (n=23) of patients with type 2 diabetes mellitus. 49 In addition, a prospective randomised study recently reported that rosiglitazone treatment for six months significantly reduces in-stent restenosis in type 2 diabetes mellitus patients. 50 In contrast, in a small randomised trial, rosiglitazone did not influence restenosis after coronary stenting in patients with type 2 diabetes mellitus, despite an improvement in glycaemic control. 51 Markers of subclinical inflammation, such as CRP and IL-6, have been shown to be independent predictors of CVD risk. 52 It is noteworthy that the anti-inflammatory effects of PPARγ agonists have been seen in humans. Indeed, both rosiglitazone and pioglitazone treatment in patients with type 2 diabetes mellitus reduces plasma levels of CRP and IL-6. 44, 53 The magnitude of reduction of circulating inflammatory markers observed after TZD treatment was comparable to the lowering seen with the lipid-lowering statins. In addition, treatment with TZDs is associated with a reduction of other plasma markers of chronic vascular inflammation, such as PAI-1, E-selectin, fibrinogen and also MMP-9, effects which may contribute to an improved haemostatic function. 54 Of note, treatment with TZDs significantly increases serum adiponectin levels in patients with type 2 diabetes mellitus or the metabolic syndrome. 44, 55 In the light of the emerging concept of a direct vascular anti-atherogenic action of adiponectin, this induction of adiponectin production could participate in the beneficial effects of TZDs on vascular function.
There are also concordant data for a role of TZDs in regulating blood pressure. Indeed, both rosiglitazone and pioglitazone significantly lower both systolic and diastolic blood pressure in hypertensive patients with or without type 2 diabetes mellitus. 56, 57 Such haemodynamic improvement, with a decrease in vascular resistance, seems to be directly correlated to improved insulin sensitivity. 58 Finally, there is much debate concerning some apparently different effects of rosiglitazone and pioglitazone on blood lipids. Although pioglitazone treatment lowers serum concentrations of LDL-C and TG, rosiglitazone treatment does not appear to decrease TG, but increases the levels of LDL-C. 59, 60 A putative molecular mechanism for these differences may be that pioglitazone has, albeit limited, PPARα activity. On the other hand, TZDs improve LDL particle density, causing a shift from small, dense LDL particles to larger, buoyant LDL particles, which are thought to be less atherogenic. These changes in LDL-C density elicited by TZDs might be more meaningful than the changes in overall LDL-C levels. Clearly, there is a need for direct, double-blind comparison of these two agents to assess the clinical impact of these changes in plasma lipid profile.
REVIEW
PPARα agonists
Several clinical trials have demonstrated that fibrates improve the cardiovascular risk profile. Several angiographic intervention trials, such as the LOCAT, the DAIS, and the BECAIT demonstrated beneficial effects of fibrates on atherosclerotic lesion progression. [61] [62] [63] Furthermore, primary and secondary prevention trials, including the VA-HIT and the Helsinki Heart Study, have demonstrated a decreased incidence of cardiovascular events after fibrate treatment. 64, 65 In addition, the SENDCAP study, which focused on patients with type 2 diabetes mellitus, reported that bezafibrate decreases the incidence of myocardial infarction in this high-risk population. 66 However, it remains difficult to distinguish the relative contributions of improved dyslipidaemia (i.e. increased HDL-cholesterol and decreased hypertriglyceridaemia) from direct PPARα-mediated vascular effects in the overall therapeutic activity of fibrates. The results of the ongoing FIELD trial will give additional answers on the vascular protective role of fibrates in the diabetic population.
Some studies have demonstrated that pleiotropic vascular effects of fibrates occur in humans. Treatment with fibrates of type 2 diabetes mellitus patients results in improved postischaemic FMD of the brachial artery, 67 suggesting an improvement of endothelial function. This effect on ECs may be independent of the lipid-lowering effect of fibrates, since aggressive lipid-lowering therapy with statins does not improve endothelial function in type 2 diabetes mellitus patients without CHD. 68, 69 These findings remain somewhat controversial 70, 71 and obviously need to be clarified.
PPARα agonists also reduce vascular inflammation, since dyslipidaemic patients treated with fenofibrate display decreased plasma levels of IL-6, CRP and fibrinogen, the production of which is controlled by cytokines. 7, 72 Fibrates may additionally modulate thrombosis and promote fibrinolysis by reducing PAI-1 plasma levels. 31 
Perspectives
In this review, we did not discuss the role of PPARs in the control of heart function. The effects of PPARγ agonists in heart failure is controversial. 73 On the one hand, several studies in rodents have demonstrated a potential benefit of PPARγ agonists in improving contractile function and post-ischaemia heart recovery. 74 These cardioprotective effects of TZDs are independent of glucose lowering and may be due to anti-inflammatory properties of the drugs. On the other hand, clinical reports have highlighted some potential side effects which may worsen heart function. Indeed, weight gain and peripheral oedema may occur in certain patients treated with TZDs. It should be noted that the weight gain obtained with TZDs may be associated with an increase in subcutaneous adipose tissue and a concomitant decrease in visceral fat, which may explain in part the improvement in glycaemic control despite an overall increase in body weight. Fluid retention is also another potential cause of increased body weight. The incidence of CHF in TZD-treated patients is very low, but appears higher in patients already treated with insulin who receive higher doses of the TZDs and who have other risk factors for CHF. 75 A consensus statement from the USA notes that TZDs may be used initially at a lower dosage in patients with NYHA class I or II heart failure, as long as close observation is provided. However, in patients with NYHA class III or IV heart failure, TZDs should not be prescribed. 76 In Europe any evidence of heart failure (NYHA I-IV) is a contraindication to the use of TZDs. Prospective clinical trials are currently under way to further define the cardiovascular safety and efficacy of TZDs in diabetic patients with heart failure.
From a therapeutical perspective, the concept of SPPARM is of great interest and potentially offers large clinical applications. The SPPARM concept is based on the observation that different PPAR ligands can modify the three-dimensional conformation of the ligand-receptor complex, leading to differential interaction with cofactors or other transcription factors. 77 Thus, different ligands could activate or repress specific target genes depending on the cell type. As an example, they could induce favourable PPARγ-mediated effects on the vasculature without stimulating adipocyte differentiation. 78 More advanced is the development of novel PPAR agonists, such as combined PPARα/PPARγ agonists. Preclinical data in rodents indicate that these activators improve both glucose and lipoprotein metabolism. 79 Some of these combined PPAR agonists are presently being examined in phase II and III trials, such as muraglitazar and tesaglitazar. 80 However, safety parameters should be carefully monitored such as weight gain and heart failure. Moreover, some of these novel compounds have induced carcinogenesis in rodents. To overcome potential unfavourable effects, several laboratories are now focusing on partial PPARα/γ activators, which may combine the beneficial metabolic effects of both PPARα/γ activation with fewer undesirable side effects.
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Key messages
• PPARs control several steps of atherogenesis by regulating target genes
• Preclinical studies strongly suggest a potential beneficial vascular effect of PPAR agonists
• Interventional studies are needed to validate the cardiovascular protective effect of PPAR agonists in humans 
